A Study of Nemtabrutinib Versus Comparator
Phase 3
1,200
about 8.7 years
18+
41 sites in AL, AZ, CA +19
About this study
This trial is testing nemtabrutinib compared to investigator's choice of ibrutinib or acalabrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if nemtabrutinib is as effective as these other medications, and whether it helps patients live longer without their cancer getting worse.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Acalabrutinib
- 2.Take Ibrutinib
- 3.Take Nemtabrutinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
acalabrutinib, ibrutinib, kinase inhibitor
oral (Oral Capsule), oral (Oral Tablet)
Primary: Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR), Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICR
Secondary: Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR, Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience One or More Adverse Events (AEs), Overall Survival (OS)
Oncology